Poolbeg Pharma为癌症和肥胖药物试验筹集了4.1亿英镑,将其跑道延长到2027年。 Poolbeg Pharma raises £4.1M for cancer and obesity drug trials, extending its runway to 2027.

英国生物技术公司Pharma正在筹募410万英镑, 资助其主要药物的临床试验:POLB 001, 癌症免疫疗法, 以及肥胖症的口服治疗。 Poolbeg Pharma, a UK biotech firm, is raising £4.1 million to fund clinical trials for its lead drugs: POLB 001, a cancer immunotherapy, and an oral treatment for obesity. 这笔资金将把该公司的财务跑道延长到2027年,预计到2025年底,POLB 001阶段2a审判的第一位病人将进入2027年。 The funds will extend the company's financial runway to 2027, with the first patient in POLB 001's Phase 2a trial expected by the end of 2025. 股权问题按市场12%的折扣定价,得到公司董事的支持,认为对股东公平。 The equity issue, priced at a 12% discount to the market, is backed by the company's directors as fair for shareholders.